Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.44 |
| ▸ | GRM5 | P41594 | 10/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129849 | 0.93 | PTGDR2 (0.43) | PTGDR2GRM5TMEM97SIGMAR1DPP4 | |
| SCHEMBL16100169 | 0.91 | PTGDR2 (0.42) | PTGDR2GRM5TMEM97SIGMAR1 | |
| SCHEMBL16099812 | 0.90 | GRM5 (0.40) | PTGDR2GRM5TMEM97SIGMAR1DPP4 | |
| SCHEMBL16100641 | 0.86 | FAAH (0.45) | PTGDR2GRM5 | |
| SCHEMBL16100107 | 0.86 | GRM5 (0.36) | PTGDR2GRM5TMEM97SIGMAR1DPP4 | |
| SCHEMBL16093646 | 0.84 | ENPP2 (0.40) | PTGDR2GRM5SIGMAR1 | |
| SCHEMBL16103128 | 0.83 | GRM5 (0.36) | PTGDR2GRM5TMEM97SIGMAR1DPP4 | |
| SCHEMBL16100138 | 0.80 | ENPP2 (0.42) | — | |
| SCHEMBL25411353 | 0.80 | MEN1 (0.48) | GRM5TMEM97SIGMAR1CYP4F2CYP4A11 | |
| SCHEMBL16099623 | 0.80 | TACR1 (0.39) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | PTGDR2 444/4885GRM5 1744/4885TMEM97 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.